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Purpose: To evaluate the efficacy of intravascular stents used to treat long-segment 
stenoses and occlusions of the superficial femoral artery (SFA) after suboptimal angio- 
plasty. 
Methods: Fifty-eight limbs in 55 patients who underwent stenting of the SFA were 
identified from a vascular registry. Indications for steut placement after suboptimal PTA 
included flow-limiting dissection, residual pressure gradient (>15 mm Hg) or stenosis 
(>30%), or failure to establish initial patency. Lesion length ranged from 6 to 35 cm 
(mean, 16.5 cm). Eudpoints for primary patency were: restenosis of > 50%, reocclusion, 
or diminution of the postprocedure ankle-brachial index greater than 0.15. 
Results: The mean ankle-brachial index improved from 0.48 -+ 0.19 to 0.71 -+ 0.23 (p = 
0.001). Primary patency rates by Kaplan-Meier estimates at 1 month, 6 months, and 1 
year were 88%, 47%, and 22%, respectively. Secondary pateucy rates were 94% at I month, 
59% at 6 months, and 46% at 1 year. The median time to reaching an endpoint of 
restenosis or reocdusion was 6 months primarily and 9 months secondarily. Clinical 
improvement a the time of latest follow-up occurred in 56% of patients (mean, 13.8 
months). Periprocedural complications occurred in 24.5% of patients with the first 
intervention. The only factor that favorably influenced outcome was improvement in
clinical category after the procedure (p = 0.001). 
Conclusions: There was a high incidence of restenosis and reocclusion with long-segment 
SFA disease that required stents to achieve initial success. Despite close surveillance and 
reinterventiou, anatomic patency at 1 year was poor. However, clinical benefit was 
maintained in the majority of patients. The outcome was similar in the claudication 
population compared with those who had limb-threatening ischemia. Percutaneous 
revascularization f long-segment SFA disease requiring stents should be reserved for 
patients with critical limb ischemia for which no reasonable surgical alternative xists. 
(J Vasc Surg 1997;25:74-83.) 
Percutaneous transluminal ngioplasty (PTA) has 
been modestly successful (43% to 73% patency rates 
at 1-year follow-up) in treating atherosclerotic dis- 
ease of  the superficial femoral artery (SFA)? -3 The 
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results for long-segment (>10 cm) lesions are less 
durable (20% to 69% patency rates at 1 year). 2,4,s 
Initial technical failure occurs in 10% to 33% of SFA 
procedures, making intravascular stents an attractive 
alternative for the salvage of suboptimal PTA. 2,6,7 It 
was hoped that stents would lead to improved pa- 
tency rates in long-segment disease that is typically 
prone to restenosis and reocclusion after PTA alone. 
Several SFA stent studies have demonstrated 1-year 
primary patency rates between 29% and 68% using 
Wallstcnts 8-11 and 81% using Palmaz stents. 12,13 
The purpose of this study was to evaluate the 
efficacy of intravascular stents for long-segment dis- 
case of the SFA in patients with suboptimal PTA. We 
report he initial and late clinical, hemodynamic, and 
angiographic results of these interventions. 
JOURNAL OF VASCULAR SURGERY 
Volume 25, Number 1 Gray et al. 75 
Table I. Patient demographics (mean age, 
62 years; range, 34 to 81 years) and clinical 
limb status in 55 patients who underwent 
superficial femoral artery PTA and stenting 
Characteristic No. fpatients (%) 
Male 32 (56) 
Diabetes mellitus 26 (46) 
Current smokers 36 (64) 
Clinical ischemic category: 
0-asymptomatic 0 (0) 
1-mild clandication 0 (0) 
2-moderate claudication 6 (10) 
3-severe claudication 22 (39) 
4-rest pain 10 (17) 
5-minor tissue loss 19 (33) 
6-major tissue loss 0 (0) 
Table I I .  Anatomic characteristics before 
PTA and stenting of SFA atherosclerosis in 
58 limbs 
Characteristic No. flimbs (%) 
Occlusion/stenosis 52 (89) 
Site of involvement: 
Proximal SlZA 14 (24) 
Mid SFA 8 (14) 
Distal SFA 18 (31) 
Entire SFA 18 (31) 
Lesion length: 
6-15 cm 29 (50) 
16-35 cm 29 (50) 
No. of patent tibial arteries: 
0-1 arteries 36 ( 2) 
2-3 arteries 22 (38) 
PAT IENTS AND METHODS 
Patients treated in the peripheral interventional 
laboratory at The Cleveland Clinic Foundation were 
prospectively entered into a vascular egistry. From 
August 1992 to December 1995, 267 patients were 
identified as having PTA of the SFA. Fifty-five of 
these patients (58 fimbs) had intravascular stents 
placed because of suboptimal results of  angioplasty 
alone. Suboptimal PTA was defined as residual ste- 
nosis >30%, residual pressure gradient of >15 mm 
Hg,  flow-limiting dissection, or complete occlusion 
after PTA. 
Patient demographics and clinical limb status at 
the time of intervention are listed in Table I. Accord- 
ing to reporting standards, 50% of the treated pa- 
tients had clandication; the remainder were treated 
for critical imb ischemia. 14 The mean preprocedural 
resting ankle-brachial index was 0.48 + 0.19. Lesion 
characteristics, infrapopliteal runoff, and reference di- 
ameter of  the SFA are shown in Tables I I  and II I .  
Poor runoff, defined as zero or one patent tibial or 
peroneal artery, was present in 62% of cases; two or 
more patent vessels were identified in 38%. The indi- 
cations for stent placement were significant residual 
pressure gradient (>15 mm Hg) or stenosis (>30%) 
in 48% (28 limbs) and PTA-induced dissection or 
absence of  flow in 52% (30 limbs). 
Endovascular technique. Before intervention, a 
diagnostic angiogram was obtained from the con- 
tralateral femoral approach. Proximal SFA lesions 
were treated initially from this approach. Middle or 
distal SFA lesions were treated from the ipsilateral 
common femoral artery using an antegrade ap- 
proach. Retrograde cannulation of the popliteal ar- 
tery was required in six limbs (10%). All interventions 
were performed with percutaneous access. 
Table I I I .  Summary of endovascular 
procedures on 55 patients with 58 limbs who 
underwent PTA and stenting (21 limbs 
underwent reintervention [ 36%]) 
Characteristic Percent of limbs No. of stents per limb 
Balloon dilation size 
5 mm 32 
6 mm 60 
7 or 8 mm 8 
Adjunctive thrombolysis 
With primary procedure 12 




Wallstent and Palmaz 4 
mean 2.21; (1-5) 
mean 3.00; (1-7) 
mean 2.50; (1-2) 
Chronic occlusions were crossed with a hydro- 
philic guidewire. Contrast injection then established 
wire position within the true lumen of the artery 
distal to the object lesion. Systemic heparin (5000 U 
bolus) was given to achieve an activated clotting time 
greater than 250 seconds. Angioplasty was then per- 
formed using a low-profile, high-pressure balloon 
with variable inflation times (between 1 and 5 min- 
utes). Angiography and residual pressure gradient 
measurement were repeated after removal of the bal- 
loon, before stent deployment. 
The selection of stent type was operator-depen- 
dent, but the Wallstent was generally preferred be- 
cause of its longer length and ease of  delivery from 
the contralateral pproach. Palmaz stents were more 
frequently used to treat short dissection flaps. Multi- 
ple stents were used in 81% of patients, with overlap 
minimized to 3 mm if possible (Table I I I).  After 
release of the Wallstent, intrastent balloon dilation 
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was required. The most frequently used Wallstent 
was either a 10 mm (diameter) x 94 mm (length) or 
8 mm × 80 mm. The most frequently used Palmaz 
stent was the P294 (29 mm length). All stents were 
delivered through 7F sheaths. 
Adjunctive thrombolysis with urokinase or tissue- 
plasminogen activator was used before angioplasty in
seven limbs (12%). The fibrinolytic agent was deliv- 
ered locally through a multiside-hole catheter placed 
at the time of the diagnostic study. The duration of 
infusion was typically 8 to 16 hours, with angioplasty 
performed immediately after lysis. Of the 21 patients 
who underwent reintervention, 19% were given 
thrombolytic therapy for recent thrombotic occlu- 
sion, after which repeat angioplasty (100%) and addi- 
tional stents (33%) were used. 
Most patients were treated with continuous hep- 
arin infusion after sheath removal, followed by con- 
version to oral warfarin. Oral anticoagulant therapy 
was continued as long as the vessel remained patent. 
Aspirin was given before the procedure and was used 
in conjunction with oral anticoagulation if tolerated. 
Follow-up. Follow-up physical examinations 
were routinely performed in the outpatient depart- 
ment at 1, 3, 6, 12, and 24 months. Fifty-seven of 
the 58 limbs were observed for a mean of 13.8 _+ 
12.5 months. One patient was lost to follow-up. 
Segmental limb pressures, pulse volume recordings, 
and duplex ultrasound scans of the stented segments 
were performed at each follow-up. Angiographic 
scans were repeated if restenosis or reocclusion was 
identified in those patients considered for reinterven- 
tion. Angiographic scans were not repeated for those 
patients whose medical risk of  reintervention was too 
great or whose limbs had worsened to the point of 
inevitable amputation. Some claudication patients 
with a viable limb and occluded SFA stents were not 
offered reintervention at the discretion of the attend- 
ing physician. 
Restenosis was defined as (1) >50% stenosis 
within or immediately adjacent o the stent; (2) a 
reduction in the ABI of greater than 0.15 from the 
maximum postprocedure ABI; or (3) evidence of 
restenosis with duplex ultrasound. 15 Duplex ultra- 
sound criteria for significant SFA stenosis were dou- 
bling of the flow velocity from the proximal adjacent 
segment or peak systolic velocity greater than 200 
cm/sec with loss of the reverse Doppler component 
and decreased systolic velocity beyond the stenosis. 15 
Primary angiographic patency was defined as pa- 
tency of the treated artery without restenosis or reoc- 
clusion on follow-up. Secondary patency was 
achieved in restenosed or reoccluded arteries that 
were recanalized to establish antegrade flow. Clinical 
patency was defined as improvement by at least one 
clinical category. The limb status was also assessed 
using a scale from + 3 to -3  as outlined by Ruther- 
ford 16 (Table I). 
Statistical analysis. Demographic and clinical 
data are expressed as proportions for categoric vari- 
ables and means and standard eviations for contin- 
uous variables. Ankle-brachial indexes before and 
after the procedure were compared with paired t test. 
Kaplan-Meier estimates of time until recurrence and 
time-to-event curves for primary patency and secondary 
patency rates were used. A p value of 0.05 or less was 
considered to be statistically significant. All tests were 
two-tailed. Statistical analyses were carried out using 
SAS version 6.0 (Statistical Systems, Cary, N.C.). 
RESULTS 
Of  57 limbs that had stenting of the SFA, 40 
reached an endpoint of  restenosis (20) or occlusion 
(20). The remaining 17 were censored uring fol- 
low-up. Twenty-one (53%) of the 40 failed limbs 
went on to reintervention. Of these 21, 15 were 
found to have significant restenosis but remained 
patent; six were occluded. Fourteen of the 21 failed 
again, with 11 occlusions and three restenoses. Eight 
patients had more than one reintervention. 
Ninety-five Wallstents were deployed in 43 limbs; 
19% required one stent, 46% required two stents, and 
35% required three or more stents (maximum Of five) 
to cover the entire diseased segment. Ninety-three 
percent of the stents were deployed at the time of the 
primary procedure. The remainder were deployed on 
reintervention. 
Thirty-six Palmaz stents were deployed in 12 
fimbs. The average number of stents per limb was 
three (range, one to seven). Thirty-one (86%) were 
deployed uring the primary procedure; five (14%) 
were deployed at reintervention. Two limbs received 
both types of stents: Wallstents to cover long-seg- 
ment disease, with a Palmaz stent placed precisely at 
the origin of  the SFA. No reintervention was per- 
formed in either of these patients. 
The mean resting ABI before intervention was 
0.48 + 0.19. At the time of latest follow-up, the 
mean ABI remained elevated at 0.71 + 0.23. Fifty- 
nine percent maintained an improvement greater 
than 0.15 in the ABI at a mean of 13.8 months of 
follow-up. Improvement in limb status of  at least one 
clinical category was maintained in 56% of patients at 
this same follow-up interval (Table IV). No change 
in clinical status was seen in 14%. There was a decline 
of at least one clinical category in 30%. 
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Table IV. Clinical limb status after PTA 
and stenting of SFA atherosclerosis at a mean 
of 13.8 months follow-up 
Limb status No. of limbs (%) 
+ 3 marked improvement 13 (22.8) 
+2 moderate improvement 15 (26.3) 
+ 1 mild improvement 4 (7.0) 
0 no change 8 (14.0) 
- i  mild worsening 3 (5.3) 
-2  moderate worsening 7 (12.3) 
-3  marked worsening 7 (12.3) 
Follow-up data are available in 54 of 55 patients 
(57 of 58 limbs), with physical examination, pulse 
volume recordings, and duplex ultrasound examina- 
tions. Arteriographic reexamination was performed 
in 21 of the 40 limbs (53%) that failed. Fig. 1 dem- 
onstrates the Kaplan-Meier curves for primary and 
secondary patency data. The primary patency rate, 
using the endpoints ofrestenosis or reocclusion, was 
88% at i month, 47% at 6 months, 22% at 1 year, and 
12% at 2 years. Secondary patency rates in 21 patients 
were 94% at 1 month, 59% at 6 months, 46% at 1 
year, and 11% at 2 years. 
Lesion length, occlusions versus stenoses, num- 
ber or type of stent, presence of diabetes mellitus, 
preprocedural nlde-brachial index, smoldng status, 
or use of thrombolytic therapy were not statistically 
significant factors with respect o the primary end- 
point. A statistical comparison between the differ- 
ences in balloon diameter did not reach significance 
(p = 0.06), but there was a trend favoring dilations 6
mm or greater. The only factor in subgroup analysis 
that favorably influenced outcome was an improve- 
ment in clinical category after the procedure (p = 
0.001). 
Table V compares the change in clinical category 
for chronic limb ischcmia from the preprocedure to
the postproccdure category at the latcst follow-up 
interval. Overall, 31 of 57 limbs (54%) maintained an 
improvement in at least one category. Twenty-eight 
percent remained in the same category, and 18% 
worsencd. In the six patients with moderate claudi- 
cation, two improved to an asymptomafic state, 
whereas most remained in the modcrate claudication 
category after the procedurc. Sixteen of the 22 pa- 
tients (73%) with severe claudication improved; two 
patients worsened. Fifty percent of the 10 patients 
with ischcmic rest pain improved; 30% worsencd, 
one requiring a major amputation. In those with 
minor tissue loss beforc their procedure, 42% im- 
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Fig. 1. Kaplan-Meier life table results of PTA and stenting 
for long-segment SFA atherosclerotic d sease. Primary (solid 
line) and secondary (dotted line) patency curves are depicted. 
proved clinically, but four limbs went on to major 
amputation. The amputation rate in this patient pop- 
ulation was five of 57 limbs (9%). 
Of these five major amputations, three were im- 
proved enough to lower the level of amputation from 
above-knee to below-knee. One patient required bi- 
lateral below-knee amputations for gangrene. On 
failure of the SFA-stented segment, eight patients 
went on to surgical bypass, four of whom went on to 
minor (toe or transmetatarsal) mputation. 
There were seven major and seven minor compli- 
cations (24.5%) at the time of primary intervention. 
Of the major complications, there were four deaths 
within 30 days of the patients' initial procedures. 
Three of these patients were designated "do not 
resuscitate" because of preexisting multiple medical 
problems that were complicated by the procedure. 
Two of these three died of congestive heart failure. 
The third death occurred after emergency surgical 
repair of rapidly expanding bilateral groin hemato- 
mas after thrombolytic therapy. The fourth death 
occurred from causes unrelated to the procedure, 
after discharge, but within 30 days. There were six 
additional deaths within 13 months of the proce- 
dure. The periprocedural mortality rate in this group 
was 7% at 30 days and I8% at 13 months. Two 
patients bled after thrombolysis; each required trans- 
fusion (4 units). One infected groin hematoma re- 
quired additional hospitalization for surgical de- 
bridement, packing, and intravenous antibiotics. 
Five of the seven minor complications were cath- 
eter entry-site pseudoaneuysms that were success- 
fully compressed with ultrasound-guided compres- 
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Table V. Comparison of the clinical categories of chronic limb ischemia from preprocedure status to 
postprocedure status at time of latest follow-up 
Preprocedure clinical category 
(57limbs) 
Moderate Severe Ischemic Minor 
daudieation cla~dication rest pain tissue loss Totals 
Postoprocedure clinical category 
Asymptomatic 2 3 1 0 10.5% 
Mild claudication 0 2 0 1 5.2% 
Moderate claudication 3 11 1 1 28.0% 
Severe claudication ] 4 3 5 22.8% 
Ischemic rest pain 0 1 2 1 7.0% 
Minor tissue loss 0 1 2 7 17.5% 
Major tissue loss 0 0 1 4 8.7% 
Totals 10.5% 38.6% 17.5% 33.3% 
sion. The other two patients had duplex evidence of 
arterial dissections near previously placed stents that 
required an additional stent o correct. 
On reintervention there were three complications 
in two patients. Two bleeding episodes were the 
result of thrombolytic therapy. A balloon rupture 
occurred while dilating a previously placed stent; it 
required surgical removal. 
DISCUSSION 
The use of intravascular stents improve the initial 
technical success of SFA angioplasty by salvaging 
those procedures with residual hemodynamic flow 
disturbances, sqa However, restenosis and reocclu- 
sion are significant intermediate and long-term limi- 
tations in providing durable patency for long-seg- 
ment SFA disease. Our results suggest short-term 
benefit (6 months) with the primary procedure, with 
secondary interventions adding only several more 
months of patency. Clinical benefit was sustained in 
some patients despite aloss of arterial patency. Over- 
all, these patients had severe atherosclerotic disease, 
as evidenced by a mean baseline ankle-brachial index 
of only 0.48, with more than 60% having no patent 
or only one patent tibial or peroneal artery. More 
than 50% had limb-threatening ischemia. The high 
mortality rate on follow-up also attests to the diffuse 
atherosclerosis and high operative risk. 
The available literature suggests that patients 
with short-segment SFA disease may benefit from 
percutaneous revascularization with stenting, sqa Ta- 
ble VI summarizes the literature according to lesion 
length and type of stent. Most of these stents were 
placed in claudication patients with short-segment 
stenoses, whereas most patients in the current series 
had long-segment SFA lesions. The indication for 
stent placement in most of these studies was subop- 
timal angioplasty or recurrence after previous angio- 
plasty, which is consistent with this series. The re- 
ported patency rates in many of these studies are 
based on clinical findings, not necessarily on angio- 
graphic patency. Although these studies uggest that 
Wallstents are not as likely to remain patent as 
Palmaz stents, no comparative trials are available to 
date. We found no difference in patency rates be- 
tween these two types of stents; they were equally 
prone to restenosis and occlusion. 
The possible causes of poor patency rates in pa- 
tients with long-segment SFA disease include incom- 
plete apposition of the stent o the vessel wall, small 
post-deployment luminal diameter, or decreasing 
flow velocity through the SFA. Intrinsic characteris- 
tics of the stent, including metal composition, 
thrombogenecity, and flexibility, may also play a role. 
All of these factors may promote myointimal hyper- 
plasia, restenosis, and thrombosis. 
Restenosis can be seen throughout the length of 
the stents, and particularly at sites of stent overlap. 12 
This arterial reaction may be more significant with 
underdeploymentof stents or with stents not com- 
pletely imbedded into the vessel wall. This separation 
favors the deposition of fibrin and thrombus, perhaps 
inhibiting reendothelization. Further thrombus 
propagation can lead to acute thrombosis or the 
secondary formation of myointimal hyperplasia) 7 
Intravascular ultrasound examination after stent de- 
ployment is able to identify these gaps between the 
vessel wall and stent struts. These gaps may be diffi- 
cult to correct in long tubular stents despite long- 
duration, high-pressure inflations. Wallstents must 
shorten in length to increase in diameter; once de- 
ployed, further increase in stent diameter may be 
difficult to achieve. In contrast, Palmaz stents 
shorten minimally on dilation and can theoretically 
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Table VI. Summary of  literature regarding use of intravascular stents for superficial femoral artery 
atherosclerosis (studies are listed in order of increasing mean lesion length with patencies reported at 
12 months follow-up, except for Zollikofer 9which is at 20 months) 
Primary Secondary 
No. of limbs and Pretreatment Lesion patency patency 
Author Stent ype % claudicators occlusion length Restenosis rate rate 
White et al.i7 W 32/94% 47% 3.7 cm 28% 75% 93% 
Henry et al32 P 126/93% 33% 3.8 cm 13% 81% 96% 
Martin et al. 18 W 90/77% 35% 5.7 cm 22% 61% 84% 
Saproval et al.n W 22/86% 90% 6.2 cm 24% 49% 67% 
Rousseau et al? W 40/78% 30% 6.2 cm 10% 68% 76% 
Bergeron et al.13 p 42/79% 57% 7.6 cm 19% 81% 89% 
Do-Daft-Do et al.10 W 26/85% 100% 8.6 cm 38% 59% 69% 
Zollikofer et al.9 W 15/76% 80% 13.5 cm 43% 29% 43% 
Gray et al. P,W 57/50% 89% 16.5 cm 39% 22% 46% 
Totals: 450/80% 62% 8.0 cm 26% 58% 73% 
W, Wallstent; P, Palmaz stents. 
be imbedded more completely. This may be offset by 
the need for multiple stents. 
Henry et al.~2 reported a restenosis rate of  33% 
when more than four Palmaz stents were placed in 
the SFA, as compared with a 4.4% restenosis rate for 
a single stent in the proximal SFA. This 4.4% inci- 
dence of restenosis with Palmaz stents when used in 
short-segment proximal SFA disease increased to 
9.8% in the mid-SFA, and to 18.5% in the distal 
SFA? 2 As the flow velocity and shear stress decrease 
as blood flows more distally in the SFA, there may be 
greater platelet/fibrin deposition on the stent struts, 
perhaps accounting for higher rates of  restenosis37 
Muscular traction on the artery or stent during am- 
bulation may also contribute to the flow dynamics, 
although its clinical impact is unknown? 8
The amount of the vessel wall covered by a me- 
tallic stent may also impact restenosis. Stents proba- 
bly cover 13% to 30% of the vessel wall, depending 
on the size of artery and the size and type of stent 
used. 22 Wallstents have 12 metal strands in a flexible, 
spiral configuration that creates a more dense me- 
tallic surface when deployed, compared with the 
rigid, fenestrated Palmaz stent. By deploying a 1-0 
mm diameter Wallstent in a 5 mm or 6 mm vessel, 
much more of  the vessel wall will be covered. This 
may be equally important in deciphering the dy- 
namic aspects of  tissue:stent interaction regarding 
restenosis. 
Smaller luminal diameters after stent placement 
have been shown to be a significant risk factor in 
coronary artery restenosis and acute thrombosis? 9 
Saproval et al.n made this observation with SFA 
disease, noting that arteries < 5 mm in diameter have 
a lower patency rate with PTA and stent placement. 
We were unable to note a statistically significant 
difference in our series, but a trend favoring larger 
postintervention diameters might have reached sig- 
nificance with greater numbers. Residual stenosis af- 
ter intervention also decreases luminal diameter, and 
in heavily diseased, calcified arteries may be difficult 
to totally eliminate, even with stents. Residual pres- 
sure gradients greater than 15 mm Hg also nega- 
tively impact restenosis rates, z°,21 Despite improved 
resolution of pressure gradients with stents, resteno- 
sis still occurs. 
Neither our primary nor secondary patency rates 
stabilized uring the observation period. Regardless 
of whether PTA alone or restenting was used on 
reintervention, restenosis or reocclusion occurred in 
some patients. This differs with other published ata 
and may be partly attributable to the high incidence 
of pretreatment occlusion in these patients, q° Do- 
Dai-Do et al?0 noted a restenosis rate of 38% in 26 
patients with femoropopliteal occlusions; Rousseau 
et al.s reported an overall restenosis rate of only 10%, 
but only 30% were occluded at the time of primary 
intervention. 
It is not known whether superficial femoral artery 
stents require warfarin anticoagulation. 8,1s Consider- 
ing the diffuse nature of the disease, the small caliber 
of the artery, and the generally poor run-off, we 
elected to use heparin and warfarin routinely in this 
series. This likely contributed to the high complica- 
tion rate (24.5%), most of which were access-site 
bleeding and pseudoaneuysm formation. The Wall- 
stent trial also noted a high bleeding complication 
rate (16.7%) in treating femoral disease. 23 
Treatment of complete occlusions adds to the 
difficulty and complexity of the procedure when 
compared to treating stenoses, thereby increasing 
complications. 1°,~2 Considering the severity of dis- 
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ease in our critically ischemic patients, the overall 
amputation rate was decreased by 50% with percuta- 
neous intervention. Those patients who failed percu- 
taneous intervention and then underwent successful 
surgical bypass also avoided major amputations. 
Restenosis, as defined in this study, identifies le- 
sions that may have minimal clinical significance. The 
duplex ultrasound criteria defining a 50% stenosis 
may only impact clinical symptoms as the activity 
level of  the patient intensifies. Likewise, a drop in the 
ankle-brachial index may be impacted by worsening 
aortoiliac or tibial disease outside of  the stented arte- 
rial segment. Consequently, despite a lowered arte- 
rial patency rate the clinical patency rate was mark- 
edly better in follow-up (Table V). 
When judging our results, with relatively low 
patency rates and high procedural complication 
rates, stenting of long-segment SFA disease seems 
like an unattractive alternative. Usually only short- 
term benefit from these procedures can be expected; 
however, when faced with no other revascularization 
option, especially in the face of multiple medical 
comorbidities that preclude operation, this short- 
term benefit may be all that is necessary in those 
patients with critical limb ischemia. Increased blood 
flow is necessary to heal ulcerations and ischemic 
tissue, but may not be needed to maintain skin integ- 
rity once healed. 
Early in this experience it seemed logical to cover 
the entire atherosclerotic lesion in the SFA with 
stents because of the excellent cosmetic (angio- 
graphic) appearance obtained. Because the restenotic 
process seems to be so consistent hroughout long 
stented segments, it may be more appropriate to 
stent only the most hemodynamically significant seg- 
ments. Other stent modifications such as heparin 
coating, z4 synthetic graft covering, 25 or intravascular 
irradiation, z6 may be the solution to avoiding the 
clinically significant secondary changes seen after 
PTA and stenting of  long-segment SFA disease. 
CONCLUSION 
Patients with suboptimal PTA for long-segment 
SFA disease that receive stents do not maintain pa- 
tency long-term. Reintervention for restenosis or re- 
occlusion improves patency, but with limited long- 
term benefit. The short-term benefit of these 
percutaneous procedures comes with a significant 
risk of  complications, primarily access-site bleeding. 
Consequently, patients with claudication should be 
treated with other methods that carry a more favor- 
able risk-benefit ratio. Patients with critical limb isch- 
emia at an increased surgical risk, however, may ben- 
efit from stenting of suboptimal PTA. 
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DISCUSSION 
Dr. Kim J. Hodgson (Springfield, Ill.). The authors 
present a retrospective r view of 267 patients who under- 
went superficial femoral artery balloon angioplasty, con- 
centrating on the outcomes of a subset of 58 patients who 
were treated with intravascular stents for suboptimal initial 
technical results of balloon angioplasty alone. Complete 
occlusions were present in 89% of the treated limbs, and 
50% of the lesions were in excess of 15 cm in length, the 
longest being 35 cm, with an average length of 16.5 cm. In 
our own endovascular p actice, we long ago abandoned 
dilatation of most lesions longer than 10 cm, especially 
complete occlusions, because of similarly poor long-term 
results to those reported today. 
This gives rise to my first set of questions. Why were 
patients with such severe disease lected for balloon an- 
gioplasty rather than surgical reconstruction, which can be 
performed under local anesthesia, if need be, to minimize 
operative risk? Was it realistic to expect o successfully treat 
such lesions without supplemental stenting, a procedure 
known to be thrombogenic in this location? 
To ameliorate the thrombogenicity of the stents, you 
adopted a policy of long-term anticoagulation therapy in 
all of your stented patients. We have observed late stent 
thrombosis in patients who had superficial femoral artery 
stents who havediscontinued their warfarin therapy or 
whose prothrombin times fall below therapeutic levels. 
Were all of your patients therapeutically anticoagulated at 
the time their interventions thrombosed? 
One of your stent implantation criteria was a pressure 
gradient across the lesion in excess of 15 mm Hg after 
balloon angioplasty alone. In at least 90% of your cases, the 
measurement of arterial pressure downstream of the di- 
lated lesion was achieved with a catheter that traversed the 
area of questionable r sidual stenosis from the upstream 
side, possibly partially obturating the vessel and creating an 
artificial pressure gradient. We have found the absence of a 
pressure gradient measured in this way to be reassuring, 
but have been unwilling to trust a positive determination 
for this reason. Can you tell us how many limbs were 
judged to have had suboptimal dditional dilatation on the 
basis of a pressure gradient measurement alone? Do you 
think that the pressure gradient in these limbs may have 
been artificially induced and that they may have fared 
better without having been stented? 
Acknowledging that dilatation and stenting of vessels 
with such severe disease is not likely to produce long-term 
benefit, there is a flip side of the argument to consider. In 
your manuscript you report that 17 limbs were censored 
because of the death of the patients, only one of which 
appeared to be directly related to the procedure. Depend- 
ing on whether the patients who died underwent single- 
limb or dual-limb procedures, this translates into a mortal- 
ity rate of 25% to 31% over the average follow-up eriod of 
13.8 months; arate so high that long-term success may not 
be a critical issue. 
Nonetheless, at the mean follow-up period of 13.8 
months, 59% of the limbs were able to maintain an increase 
of at least 0.15 in their ankle-brachial index, and 56% 
had persistence of at least one clinical category of im- 
provement. How do you reconcile these observations 
with the dismal patency results you have reported? 
Could it be that your duplex scan determinations of a 
>50% restenosis are flawed, or might a 50% restenosis, 
as determined by duplex scanning, be clinically or hemo- 
dynamically insignificant? 
In the final analysis, the data presented appear to sup- 
port our long-standing belief that even stents cannot sub- 
stitute for clinical judgment when it comes to determining 
which atherosclerotic lesions are suitable for presently 
available ndovascular interventions. 
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Dr. Bruce H. Gray. Thank you for your comments. 
As you know, we have xcellent surgical coverage at the 
Cleveland Clinic. These patients had profound levels of 
ischemia, and because of multiple medical problems our 
first option was to pursue percutaneous treatment. If suc- 
cessful, we could obviate the need of a surgical procedure. 
Unfortunately, what we have noticed through the course 
of the study period is that these patients frequently have 
recurrent disease. The purpose of these data is to show that 
the percutaneous alternative to long-segment superficial 
femoral artery disease is not a durable procedure. 
Our perception with these procedures i  that the mor- 
bidity and mortality rates were low. These data certainly 
cause us to stop and reflect on actually how tough these 
procedures are in these patients. Most of them had poor 
underlying cardiac status and truly were not good surgical 
candidates. 
Your comment about an artificial pressure gradient 
being induced by placing a 5F catheter across the lesion 
after angioplasty is performed is a good one. After success- 
ful dilatation of the superficial femoral artery to greater 
than 6 mm, one should be able to reduce the pressure 
gradient below 15 mm Hg even with a 5F catheter across 
it. If one uses the more liberal criteria for stent placement, 
that being a 5 mm residual pressure gradient, hat is hard 
to achieve with a 5F catheter across the lesion. Therefore, 
this is less of an issue because of the 15 mm Hg gradient 
threshold. 
The use of anticoagulation therapy may be a moot 
point in these patients because the underlying problem is 
predominantly that of intimal hyperplasia going on to 
significant restenosis and reocclusion. Warfarin does not 
impact he process of intimal hyperplasia. There are other 
agents that may be more beneficial, such as glycoprotein 
I IB/ I I IA inhibitors. I think that it is going to take some- 
thing dramatic to be able to halt this substantial intimal 
hyperplastic response of this active artery to the trauma 
that we induce. 
Also, your statement that 17 grafts were censored be- 
cause the patients died is inaccurate. "Censored" means 
that the patient did not reach an end point at the time of 
latest follow-up. 
Dr. Richard L. McCann (Durham, N.C.). My ques- 
tion relates to the use of warfarin. Our cardiologists have 
found in the coronary circulation that warfarin is dramati- 
cally inferior to the use of aspirin and Ticlid in terms of 
long-term patency of stented patients. You used warfarin in 
the majority of your patients. Do you have any evidence 
that it is either beneficial or harmful in this vascular bed? 
Dr. Gray. The restenosis rate seen in this series far 
surpasses any restenosis rate that is reported in the coro- 
nary literature, as far as I know. This diffuse, long intimal 
hyperplasia segment disease is far more substantial than 
what aspirin and Ticlid or warfarin can avoid. 
Dr. Geoffrey H. White (Sydney, Australia). Your ac- 
cumulated experience of femoral stenting procedures in- 
ternationally suggests that they are not of use in patients 
who have long-segment disease, in whom multiple stents 
are used with poor runoff, limb-threatened patients, high- 
risk patients, and that the use of warfarin only serves to 
increase the complication rate. The data that you have 
presented suggests that this is precisely the patient popula- 
tion in whom you are using this technique. So first, I would 
like to ask why you have reserved recanalization a d stent- 
ing precisely for those patients in whom the information so 
far suggests that it's not of use? As a corollary, I would like 
to ask what treatment you use for the patients who are 
good risks in whom you might expect his treatment to 
actually work? 
Secondly, I would also like to ask a question regarding 
restenosis. We have found that restenosis as seen on duplex 
scans often remains relatively asymptomatic and that the 
asymptomatic status of these patients may persist for sev- 
eral years despite duplex findings that show apparent reste- 
nosis >50% or even >75% within the stent. So I would be 
interested to hear whether your experience was similar to 
our experience or whether restenosis was always associated 
with recurrent symptoms in your study. 
Dr. Gray. Our clinical patency rate at latest follow-up 
was 56%, as compared with our anatomic primary patency 
rate of 22%. Our criteria of restenosis can account for our 
high prevalence of reaching the end points that were de- 
fined. That may attest o the fact that restenosis may or 
may not be clinically significant in all cases. 
There are previous data, as you know, that anticoagu- 
lation therapy may not be necessary for performing 
superficial femoral artery stenting; however, that is in 
much shorter disease segments. Long-segment disease 
throughout the superficial femoral artery is much more 
prone to restenosis and failure of our endovascular p o- 
cedures. This sets the stage for the next generation of 
percutaneous procedures, uch as stent-grafts or coated 
stents. 
Dr. Samuel S. Ahn (Los Angeles, Calif.). I rise to 
congratulate and compliment the authors for their willing- 
ness to bring these negative results to our attention, and 
also to congratulate he Program Committee for allowing 
them to do so. I think such reports are very important. 
However, I also rise to criticize the methods used in this 
study, the fact that it was done in a retrospective fashion 
using off-label products in a nonapproved fashion. 
The literature is replete with data that show that PTA 
for stenosis greater than 7 to 10 cm has very poor results; 
yet the authors treated such unfavorable sions, and then 
stented them secondarily in attempt to ball out or improve 
their situation. In the future, such studies hould be con- 
ducted in a prospective fashion under an FDA-approved 
IDE. Such behavior will provide us much more responsible 
studies, better scientific data, and better care of our pa- 
tients. 
Having said that, I would like to ask some questions. 
I'd like to find out more about the mechanism of the 
restenosis. I think 18% of your patients died; do you have 
any autopsy specimens of the treated lesions? Also, what 
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were the locations of the restenosis, were they in the body 
of the stent or at the distal or proximal ends? 
Secondly, I would like to ask you about the technique 
that you use. When you performed balloon-dilation before 
the stent went in, how many dilatations did you perform, 
and at what pressures? In my own experience I have found 
that if you keep ballooning multiple times or at higher 
pressures, or for a longer duration, you can often get rid of 
the gradient. Did you do that, or did you stent after only 
one or two inflations at a fairly low pressure? 
Dr, Gray. Technically, we used high inflation pres- 
sures up to i8 or 20 atmospheres. Preprocedural nticoag- 
ulation with heparin allows for prolonged balloon inflation 
(as long as 5 minutes) without much risk of procedural 
thrombosis. 
Restenosis seen not only at sites ofstent overlap but 
also throughout the body of the stent. Perhaps it may be a 
result of a gap present between the stent and the actual 
vessel wall. With the deployment of a long stent in the 
superficial femoral artery followed by subsequent dilation, 
these stents may not become fully adherent to the vessel 
wall, which would predispose to restenosis. 
Dr. James C. Stanley (Ann Arbor, Mich.). Dr. Gray, I
have two comments. One, I have not seen a paper that has 
damned a technology like this since a paper was presented 
at these meetings that dealt with bovine carotid grafts. I
doubt that very many people r turned home and used that 
conduit for arterial reconstructions after that, other than 
for arteriovenous fi tulas. 
The second is, just a response to Dr. Ahn, I agree that 
if someone had this technology at hand and could have 
done a prospective study, there may have been a different 
outcome in the number of patients in many centers that 
were treated with this technique. But it reminds me of a 
past president before Frank Veith, in a discussion of the 
rather nonspecific nature of trying to identify people at 
coronary risk undergoing vascular surgery, and someone 
stood up and talked about multiple gated acquisition scans 
at one of the meetings, and he said, "You've got very 
interesting data. I 'm not sure why you did this." He said, 
"If  you drive your car up to the parking structure and 
you've got 20 of them behind you and you all drive offthe 
edge, you've got a mess down in the bottom. You don't 
need to do a statistical nalysis of it." 
I must say, I have not seen dismal results worse than 
this, and I 'm not sure a prospective randomized study, if 
one has preliminary efficacy data, or safety data, would 
allow this to go to a randomized study. Many of us who sit 
on the Joint Council of these two societies have great 
certainty about similar technology being applied to carotid 
stenting with or without balloon angioplasty at this time. 
So I think there has to be some safety data. I would say that 
if someone did a preliminary study with this particular 
procedure, the safety would not be there to justify a pro- 
spective study. 
I, too, thank you for the temerity of presenting this 
material and really congratulate he Program Committee 
for presenting this to the audience. 
